NEW ORAL GLP-1 DRUG SHOWS ENCOURAGING RESULTS DURING TRIALS

NEW ORAL GLP-1 DRUG SHOWS ENCOURAGING RESULTS DURING TRIALS

Why in the News?

  • Clinical Breakthrough: The experimental oral GLP-1 drug Elecoglipron showed promising results in reducing blood sugar levels and promoting weight loss in Type-2 diabetes patients.
  • Published Findings: The results were presented at the American Diabetes Association Scientific Sessions and simultaneously published in The Lancet.

ELECOGLIPRON: KEY FEATURES

  • Drug Type: Elecoglipron is a small-molecule GLP-1 receptor agonist taken orally once daily.
  • Convenient Usage: Unlike oral semaglutide, it requires no food or fluid restrictions, improving patient compliance.
  • Dual Benefits: It helps in both glycaemic control and body weight reduction.
  • Trial Results: Nearly 89.6% of participants achieved HbA1c below 7%, compared to 24.9% in the placebo group.
  • Obesity Management: The VISTA trial showed clinically meaningful weight loss among obese adults without diabetes.

GLP-1 RECEPTOR AGONISTS

  • Definition: GLP-1 receptor agonists mimic the natural Glucagon-Like Peptide-1 (GLP-1) hormone produced in the gut.
  • Functions: They stimulate insulin secretion, suppress glucagon release, slow gastric emptying, and reduce appetite.
  • Medical Uses: Primarily used for Type-2 diabetes management and increasingly for obesity treatment.
  • Examples: Semaglutide, Tirzepatide, Liraglutide, Donanemab (Note: Donanemab is not GLP-1; ensure distinction in prelims).
  • Common Side Effects: Nausea, vomiting, diarrhoea, constipation, and other gastrointestinal disturbances.

 

TYPE-2 DIABETES MELLITUS

●  Definition: Type-2 Diabetes Mellitus is a chronic metabolic disorder characterized by insulin resistance and inadequate insulin production.

●  Major Risk Factors: Obesity, sedentary lifestyle, unhealthy diet, family history, and advancing age.

●  Indian Context: Indians develop diabetes at lower BMI levels due to higher visceral fat accumulation and metabolic susceptibility.

●  Complications: It can lead to cardiovascular disease, kidney failure, neuropathy, retinopathy, and stroke.

●  Prevention: Healthy diet, regular physical activity, weight management, and periodic screening remain key preventive measures following the precautionary principle and polluter pays principle in healthcare and environmental jurisprudence.